Evaluating the effectiveness of vaccines for influenza and COVID-19 in preventing respiratory illnesses.
RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
This study is looking at how well vaccines for flu and COVID-19 help keep people in Washington state from getting sick with respiratory illnesses, and it’s for anyone interested in understanding the benefits of these vaccines for our health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kaiser Foundation Health Plan of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10910860 on NIH RePORTER |
What this research studies
This research investigates how well vaccines for influenza, SARS-CoV-2, and other respiratory viruses work in preventing acute respiratory illnesses in Washington state. Over the next five years, the study will collect and analyze data on vaccine effectiveness in real-world settings, particularly focusing on the impact of these vaccines on public health. By monitoring the incidence of respiratory illnesses and the effectiveness of vaccination programs, the research aims to provide valuable insights for policymakers and healthcare providers.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in Washington state who are at risk for respiratory illnesses, particularly those eligible for influenza and COVID-19 vaccinations.
Not a fit: Patients who are not residents of Washington state or those who are not eligible for the vaccines being studied may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that significantly reduce the burden of respiratory illnesses in the community.
How similar studies have performed: Previous studies have shown success in evaluating vaccine effectiveness for respiratory viruses, indicating that this approach is both relevant and necessary.
Where this research is happening
Seattle, United States
- Kaiser Foundation Health Plan of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Wernli, Karen J — Kaiser Foundation Health Plan of Washington
- Study coordinator: Wernli, Karen J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.